CER Collaborative Initiative

The growing availability of different types of health information can make it challenging for decision-makers to appropriately evaluate this information and make informed decisions about treatment options. With increased private and public funding for comparative effectiveness research, there will be a greater amount of data that is drawn not only from randomized controlled trials (RCTs), but also from a wide range of other study designs (observational studies, simulations, or comparisons between studies) and sources (registries, administrative claims, or electronic medical records).
 
There is very little guidance on how to evaluate and use these studies, which leaves that information open to wide interpretation and disparate use by decision-makers. With an expected increase in the availability of comparative effectiveness research, tools and resources are needed to help formulary decision-makers navigate through this research and use it effectively to inform coverage decisions.

To provide greater uniformity and transparency in the evaluation and use of evidence for coverage and health care decision-making, the Academy of Managed Care Pharmacy, the International Society for Pharmacoeconomics and Outcomes Research, the National Pharmaceutical Council, and their respective members have joined forces as the CER Collaborative Initiative to develop tools, resources, and training materials to aid formulary decision-makers, the researchers who are developing information for use by decision-makers, the biopharmaceutical industry, and other health care stakeholders.

Tools, resources and training materials include:

Online Tools and Training. To navigate these tools and enable decision-makers to assess the evidence in a consistent manner, online tools to assess individual studies and synthesize the evidence from multiple studies, training materials, and additional resources are available. Watch the webinar below to learn more about the tools the CER Collaborative has developed.

CER Collaborative CER Continuing Education Certificate Program. The CER Collaborative, in conjunction with the University of Maryland School of Pharmacy, has developed the CER Collaborative Continuing Education Certificate, a 19-hour certificate program to guide pharmacists and other clinical decision-makers by advancing their expertise in assessing evidence and making use of the online CER Collaborative tool and resources. The program provides continuing education credits.

Assessing the Evidence: An Individual Study. A series of interactive questionnaires were developed to help decision-makers assess whether the study is relevant to their setting or decision and credible enough to include in the body of evidence. Users can store their information, share their critical appraisal with colleagues, and access their analyses over time. The Collaborative has initially focused on four research study types:

Synthesizing A Body of Evidence: Multiple Studies. Formulary decisions require rigorous evaluation of the body of evidence. Because there are different study designs (e.g., randomized controlled trials, observational studies, and simulations) each with strengths and limitations, it can make it difficult to combine and analyze the evidence in a systematic way.  

A framework was adapted to assess the comparative benefits and risks of therapies and the corresponding certainty of these benefits and risks. The framework, user guide and online tool enable users to synthesize the evidence from multiple studies in a consistent and transparent manner to guide coverage and formulary placement. Users can store their evaluation of the body of evidence, share their synthesis with colleagues, and access their evaluations over time as new information becomes available or is treatments are re-evaluated.

Newsletter Volume

E.V.I.dently June 2016

MessageNPC Looks at Updated ASCO Framework, Conversation Around ValueThe American Society of Clinical Oncology (ASCO) released its updated value...
Blog Post

CER Tweets of the Week: PIPC Briefing on Value Frameworks, Evidence-Based Medicine in Health Journalism (June 20-24, 2016)

Last week, comparative effectiveness research (CER) stakeholders tweeted about the Partnership to Improve Patient Care’s (@PIPCpatients)...
Blog Post

CER Tweets of the Week: Access to Evidence-Based Resources, Value-Based Payment Models (June 13-17, 2016)

What have comparative effectiveness research (CER) stakeholders been tweeting about recently? Last week, we saw many conversations about a new...
Blog Post

NPC’s Dr. Graff on Developing Evidence That Is “Fit for Purpose”

What information do payers feel they need to guide their coverage decisions? Jennifer Graff, PharmD, vice president of comparative effectiveness...
Press Release

Data Can Offer Critical Insights, But Roadblocks to Data Access Persist

(Washington, D.C., April 1, 2016)—Data is key to improving health outcomes and creating efficiencies in our health care system, but a new study...
Press Release

Fit for Purpose? New NPC, AcademyHealth Framework Closes Gaps Between Payer Needs and Research Answers

(Washington, DC, September 21, 2015)—Despite multi-million dollar public and private investments to tap into big data and improve the evidence...
Press Release

NPC Comments on CMS’ Announcement to Allow Broader Access to Publicly Funded Databases

(Washington, DC, June 2, 2015)—The National Pharmaceutical Council (NPC) today commented on the Centers for Medicare and Medicaid Services’ (CMS)...
Press Release

State Medicaid Directors Share Views on Comparative Effectiveness Research And Its Impact on Policy in National Pharmaceutical Council Survey

(Washington, DC, April 16, 2015)—A new survey conducted on behalf of the National Pharmaceutical Council (NPC) shows that state Medicaid directors...
Commentary and Testimony Page

The Importance of Evidence, Value, Access and Innovation in 2016

Last year, in our 2015 Health Care Outlook published in Chain Drug Review, I highlighted the recent announcement by the U.S. Department of Health and...
Commentary and Testimony Page

Chain Drug Review – Commentary: “Health Care Outlook for 2015”

This commentary was originally published in the January 5, 2015 issue of Chain Drug Review.By: Dan Leonard, President, National Pharmaceutical...
Commentary and Testimony Page

NPC Comments on PCORI Proposal for Peer Review of Primary Research and Public Release of Research Findings

November 7, 2014Dr. Joe SelbyExecutive DirectorPatient-Centered Outcomes Research Institute1828 L St., NW, Suite 900Washington, DC 20036Dear Dr....
Commentary and Testimony Page

The State of CER and the Environment for Health Care Decision Making

This month, NPC released its third annual survey on stakeholders’ views on comparative effectiveness research (CER), “The State of Comparative...
YouTube Videos

2016 Comparative Effectiveness Research and the Environment for Health Care Decision-Making

This one-hour webinar highlights the results of NPC's annual survey of comparative effectiveness research (CER) stakeholders and includes a panel...
YouTube Videos

When Is Evidence Fit for Purpose? Closing Gaps Between Researchers, Payers

Despite multi-million dollar public and private investments to tap into big data and improve the evidence available for health care decision-making,...
YouTube Videos

Comparative Effectiveness Research and the Environment for Health Care Decision-Making

During a March 26, 2015 webinar, the National Pharmaceutical Council discussed the results of its annual stakeholder survey on comparative...
YouTube Videos

Real-World Impact of Comparative Effectiveness Research Findings on Clinical Practice

National Pharmaceutical Council Chief Science Officer Robert W. Dubois, MD, PhD, discusses a peer-reviewed study suggesting that changes are needed...
Blog Post

CER Tweets of the Week: PIPC Briefing on Value Frameworks, Evidence-Based Medicine in Health Journalism (June 20-24, 2016)

Last week, comparative effectiveness research (CER) stakeholders tweeted about the Partnership to Improve Patient Care’s (@PIPCpatients)...
Blog Post

CER Tweets of the Week: Access to Evidence-Based Resources, Value-Based Payment Models (June 13-17, 2016)

What have comparative effectiveness research (CER) stakeholders been tweeting about recently? Last week, we saw many conversations about a new...
Blog Post

NPC’s Dr. Graff on Developing Evidence That Is “Fit for Purpose”

What information do payers feel they need to guide their coverage decisions? Jennifer Graff, PharmD, vice president of comparative effectiveness...
Blog Post

Tackling Data Access at Health Datapalooza

By Jennifer Graff, PharmD, NPC VP for Comparative Effectiveness ResearchWe’re looking forward to participating in Health Datapalooza next week, which...

Got CER? Educating Pharmacists for Practice in the Future: New Tools for New Challenges

This study provides an early evaluation of the CER Collaborative's training program's impact on...

Data, Data Everywhere, But Access Remains a Big Issue for Researchers

This study captures the policy inconsistencies and hurdles that can hinder use of publicly funded...
cersurvey16

2016 Comparative Effectiveness Research and the Environment for Health Care Decision-Making

NPC's sixth annual survey of stakeholder views on comparative effectiveness research (CER) and the...
  •  
  • 1 of 15
  • >